Caranx Medical announces successful world first robotic assisted transcatheter heart valve implantation in an animal
NICE, France–(BUSINESS WIRE)–Caranx Medical (‘Caranx’), a French medical device company specializing in the development of autonomous robot to democratize... Read more.
Arthur D. Little Publishes Human After All – Latest Edition of PRISM Magazine
LONDON–(BUSINESS WIRE)–Arthur D. Little (ADL) has published Human After All – the latest edition of its strategy and innovation magazine PRISM. As... Read more.
8×8 Launches Operator Connect for Microsoft Teams to Streamline Reliable Telephony Deployment and Adoption for Organizations Using Teams
8×8 is now the only Operator Connect Provider with a Native Contact Center Solution Certified to Integrate with Teams CAMPBELL, Calif.–(BUSINESS WIRE)–8×8,... Read more.
European Firms Seek New Ways to Modernize Mainframes
Companies aim to fundamentally change the role legacy systems play in the future, ISG Provider Lens™ report says LONDON–(BUSINESS WIRE)–$III #AI–Europe’s... Read more.
Automate 2024: Cincoze Will Display AI Edge Computing Solutions
TAIPEI, Taiwan–(BUSINESS WIRE)–Rugged embedded computer brand – Cincoze, will be at Automate 2024 (South Hall, Stand 1062) in Chicago, USA, on May... Read more.
Magnesium Capital closes oversubscribed inaugural Fund at €135m hard cap
LONDON–(BUSINESS WIRE)–Magnesium Capital, the Energy Transition buyout specialist, is delighted to announce the successful close of its inaugural Fund,... Read more.
Options Appoints Former Fidessa and Colt MarketPrizm Executive, James Hardcastle as VP Head of Sales, APAC
LONDON & NEW YORK & HONG KONG–(BUSINESS WIRE)–Options Technology, a trailblazer in capital markets infrastructure, today announced the appointment... Read more.
E3 Lithium Announces Upcoming Schedule for Conferences and Presentations
CALGARY, Alberta–(BUSINESS WIRE)–$EEMMF #canadianenergy–E3 LITHIUM LTD. (TSXV: ETL) (FSE: OW3) (OTCQX: EEMMF), “E3 Lithium” or the “Company,”... Read more.
MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH002
Met primary endpoint of safety: MH002 was safe and well tolerated with no evidence of adverse reactions when administered for 8 weeks. Clinical remission rate of... Read more.
MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH002
Met primary endpoint of safety: MH002 was safe and well tolerated with no evidence of adverse reactions when administered for 8 weeks. Clinical remission rate of... Read more.